Y-mAbs Therapeutics (YMAB) Insider Trading & Ownership $15.55 -0.14 (-0.89%) (As of 11/7/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Y-mAbs Therapeutics (NASDAQ:YMAB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.50%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$1.41 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$3.63 M Get YMAB Insider Trade Alerts Want to know when executives and insiders are buying or selling Y-mAbs Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address YMAB Insider Buying and Selling by Quarter Ad Behind the MarketsThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> Y-mAbs Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/16/2024Thomas GadInsiderSell30,000$12.97$389,100.00 9/13/2024Thomas GadInsiderSell65,000$13.47$875,550.00 8/26/2024Joris WilmsCOOSell5,000$14.69$73,450.00 6/10/2024Gerard BerDirectorSell722$12.00$8,664.00 6/10/2024Thomas GadInsiderSell35,000$12.03$421,050.00 5/31/2024Bo KruseCFOSell31,371$12.07$378,647.97 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/23/2024Thomas GadInsiderSell7,351$13.00$95,563.00 5/21/2024Thomas GadInsiderSell25,000$12.00$300,000.00 3/5/2024Vignesh RajahSVPSell1,711$16.53$28,282.83 12/15/2023Thomas GadInsiderSell50,000$6.61$330,500.00 12/13/2023Thomas GadInsiderSell50,000$6.58$329,000.00 12/11/2023Biotech Aps WgDirectorBuy102,863$7.01$721,069.63 12/7/2023Biotech Aps WgDirectorBuy6,183$6.50$40,189.50 11/29/2023Biotech Aps WgDirectorBuy51,837$5.97$309,466.89 11/27/2023Johan Wedell-WedellsborgDirectorBuy62,516$5.49$343,212.84 11/20/2023Thomas GadInsiderSell75,000$5.30$397,500.00 (Data available from 1/1/2013 forward) YMAB Insider Trading Activity - Frequently Asked Questions Who is on Y-mAbs Therapeutics's Insider Roster? The list of insiders at Y-mAbs Therapeutics includes Biotech Aps Wg, Bo Kruse, Gerard Ber, Johan Wedell-Wedellsborg, Joris Wilms, Thomas Gad, and Vignesh Rajah. Learn more on insiders at YMAB. What percentage of Y-mAbs Therapeutics stock is owned by insiders? 22.50% of Y-mAbs Therapeutics stock is owned by insiders. Learn more on YMAB's insider holdings. Which Y-mAbs Therapeutics insiders have been buying company stock? The following insiders have purchased YMAB shares in the last 24 months: Biotech Aps Wg ($1,070,726.02), Johan Wedell-Wedellsborg ($1,325,003.84), and Vignesh Rajah ($5,879.40). How much insider buying is happening at Y-mAbs Therapeutics? Insiders have purchased a total of 326,334 YMAB shares in the last 24 months for a total of $2,401,609.26 bought. Which Y-mAbs Therapeutics insiders have been selling company stock? The following insiders have sold YMAB shares in the last 24 months: Bo Kruse ($378,647.97), Gerard Ber ($8,664.00), Joris Wilms ($73,450.00), Thomas Gad ($3,138,263.00), and Vignesh Rajah ($28,282.83). How much insider selling is happening at Y-mAbs Therapeutics? Insiders have sold a total of 376,155 Y-mAbs Therapeutics shares in the last 24 months for a total of $3,627,307.80 sold. Y-mAbs Therapeutics Key ExecutivesMr. Thomas Gad (Age 53)Founder, Chief Business Officer & Vice Chairman Compensation: $1.05M5 recent tradesMr. Bo Kruse (Age 51)Executive VP, Secretary, Treasurer & CFO Compensation: $685.02k1 recent tradesMs. Susan Smith (Age 53)Senior VP & Chief Commercial Officer Compensation: $710kMr. Michael Rossi (Age 53)CEO, President & Director Mr. Joris Wiel Jan Wilms (Age 50)Senior VP & COO Dr. Torben Lund-Hansen M.Sc. (Age 73)Ph.D., Senior VP & CTO Dr. Steen Lisby M.D. (Age 60)M.Sc., Senior VP & Chief Scientific Officer Compensation: $393.99kMs. Courtney DuganVice President of Investor RelationsDr. Vignesh Rajah M.B.A. (Age 59)MBBS, Senior VP & Chief Medical Officer Compensation: $406.27k More Insider Trading Tools from MarketBeat Related Companies HRTX Insider Trading AMRN Insider Trading AUPH Insider Trading MRSN Insider Trading GBIO Insider Trading CPRX Insider Trading AMPH Insider Trading TWST Insider Trading ARWR Insider Trading SRRK Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors This page (NASDAQ:YMAB) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredUrgent: This election is riggedI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
